Jennifer Michele Manne-Goehler, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Chagas Disease | 14 | 2022 | 166 | 3.820 |
Why?
|
Diabetes Mellitus | 32 | 2024 | 5888 | 2.800 |
Why?
|
Developing Countries | 27 | 2024 | 2912 | 2.670 |
Why?
|
Rural Population | 27 | 2024 | 2321 | 2.530 |
Why?
|
HIV Infections | 34 | 2024 | 17532 | 2.280 |
Why?
|
South Africa | 25 | 2024 | 1873 | 2.040 |
Why?
|
Career Mobility | 2 | 2020 | 262 | 1.200 |
Why?
|
Trypanocidal Agents | 4 | 2020 | 40 | 1.170 |
Why?
|
Hypertension | 19 | 2024 | 8616 | 1.170 |
Why?
|
Nitroimidazoles | 4 | 2020 | 118 | 1.090 |
Why?
|
Triatoma | 2 | 2018 | 10 | 1.030 |
Why?
|
Insect Control | 2 | 2018 | 28 | 1.010 |
Why?
|
Oxazines | 2 | 2024 | 358 | 0.960 |
Why?
|
Insect Vectors | 2 | 2018 | 136 | 0.950 |
Why?
|
Heterocyclic Compounds, 3-Ring | 2 | 2024 | 296 | 0.930 |
Why?
|
Income | 11 | 2023 | 1876 | 0.930 |
Why?
|
Weight Gain | 2 | 2024 | 2356 | 0.890 |
Why?
|
Faculty, Medical | 3 | 2020 | 1226 | 0.870 |
Why?
|
Antiretroviral Therapy, Highly Active | 4 | 2020 | 1900 | 0.830 |
Why?
|
Poverty | 12 | 2024 | 2714 | 0.800 |
Why?
|
Cross-Sectional Studies | 45 | 2024 | 26309 | 0.770 |
Why?
|
Pyridones | 2 | 2024 | 818 | 0.770 |
Why?
|
Health Surveys | 9 | 2022 | 4055 | 0.760 |
Why?
|
Blood Pressure | 11 | 2024 | 8533 | 0.710 |
Why?
|
Body Mass Index | 6 | 2023 | 13050 | 0.700 |
Why?
|
Obesity | 10 | 2024 | 13090 | 0.700 |
Why?
|
Cardiovascular Diseases | 20 | 2024 | 15652 | 0.700 |
Why?
|
Prevalence | 28 | 2024 | 15835 | 0.690 |
Why?
|
Infectious Disease Medicine | 1 | 2020 | 50 | 0.690 |
Why?
|
Trypanosoma cruzi | 5 | 2022 | 204 | 0.630 |
Why?
|
Diabetes Mellitus, Type 2 | 9 | 2024 | 12246 | 0.620 |
Why?
|
Insecticides | 2 | 2018 | 203 | 0.620 |
Why?
|
Health Services Accessibility | 11 | 2024 | 5513 | 0.620 |
Why?
|
Nifurtimox | 2 | 2015 | 14 | 0.600 |
Why?
|
Anti-Retroviral Agents | 6 | 2024 | 1787 | 0.600 |
Why?
|
Delivery of Health Care | 5 | 2020 | 5367 | 0.570 |
Why?
|
National Health Programs | 1 | 2020 | 443 | 0.550 |
Why?
|
Social Stigma | 2 | 2024 | 788 | 0.550 |
Why?
|
Piperazines | 2 | 2024 | 2547 | 0.540 |
Why?
|
Blood Donors | 2 | 2016 | 344 | 0.530 |
Why?
|
Viral Load | 6 | 2024 | 3385 | 0.530 |
Why?
|
Longitudinal Studies | 15 | 2024 | 14762 | 0.510 |
Why?
|
Self Report | 6 | 2023 | 3771 | 0.490 |
Why?
|
Adult | 66 | 2024 | 223305 | 0.490 |
Why?
|
Humans | 122 | 2024 | 766812 | 0.480 |
Why?
|
Sex Factors | 8 | 2021 | 10619 | 0.470 |
Why?
|
Comorbidity | 7 | 2020 | 10580 | 0.460 |
Why?
|
Communicable Diseases | 2 | 2020 | 872 | 0.460 |
Why?
|
Self Concept | 1 | 2020 | 1040 | 0.460 |
Why?
|
Drugs, Investigational | 2 | 2020 | 211 | 0.460 |
Why?
|
Cause of Death | 3 | 2022 | 3717 | 0.450 |
Why?
|
Health Services Needs and Demand | 2 | 2019 | 1404 | 0.440 |
Why?
|
Male | 72 | 2024 | 364154 | 0.440 |
Why?
|
Anti-HIV Agents | 7 | 2024 | 4561 | 0.440 |
Why?
|
Rural Health Services | 1 | 2017 | 393 | 0.430 |
Why?
|
Cost of Illness | 3 | 2021 | 1949 | 0.430 |
Why?
|
Middle Aged | 61 | 2024 | 223267 | 0.430 |
Why?
|
Female | 74 | 2024 | 396532 | 0.430 |
Why?
|
Antiprotozoal Agents | 1 | 2013 | 93 | 0.420 |
Why?
|
Disabled Persons | 1 | 2023 | 1209 | 0.420 |
Why?
|
Parturition | 1 | 2017 | 453 | 0.420 |
Why?
|
Rhodnius | 1 | 2012 | 4 | 0.400 |
Why?
|
Mexico | 7 | 2024 | 769 | 0.400 |
Why?
|
Medicine | 2 | 2020 | 944 | 0.400 |
Why?
|
Educational Status | 1 | 2020 | 2510 | 0.400 |
Why?
|
Primary Prevention | 2 | 2024 | 1188 | 0.360 |
Why?
|
Antihypertensive Agents | 4 | 2021 | 2030 | 0.350 |
Why?
|
Lamivudine | 2 | 2024 | 367 | 0.350 |
Why?
|
Circumcision, Male | 1 | 2011 | 148 | 0.350 |
Why?
|
Patient Acceptance of Health Care | 3 | 2020 | 3230 | 0.340 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2783 | 0.340 |
Why?
|
Uganda | 4 | 2024 | 1353 | 0.330 |
Why?
|
Africa South of the Sahara | 5 | 2023 | 751 | 0.320 |
Why?
|
Socioeconomic Factors | 11 | 2024 | 7841 | 0.320 |
Why?
|
Achievement | 2 | 2020 | 287 | 0.320 |
Why?
|
Quinolines | 2 | 2024 | 769 | 0.310 |
Why?
|
India | 8 | 2024 | 2335 | 0.310 |
Why?
|
Blood Glucose | 7 | 2023 | 6422 | 0.300 |
Why?
|
Intensive Care Units | 2 | 2020 | 3799 | 0.290 |
Why?
|
Aged | 42 | 2024 | 171344 | 0.290 |
Why?
|
Financing, Government | 1 | 2010 | 473 | 0.270 |
Why?
|
Infectious Disease Transmission, Vertical | 2 | 2022 | 1353 | 0.260 |
Why?
|
Mass Screening | 5 | 2022 | 5454 | 0.260 |
Why?
|
Urban Population | 4 | 2024 | 2040 | 0.250 |
Why?
|
Risk Factors | 28 | 2024 | 74889 | 0.250 |
Why?
|
Hypercholesterolemia | 2 | 2023 | 1145 | 0.250 |
Why?
|
Health Services Research | 2 | 2018 | 1811 | 0.250 |
Why?
|
AIDS Vaccines | 1 | 2011 | 898 | 0.250 |
Why?
|
Health Services | 1 | 2010 | 755 | 0.240 |
Why?
|
Epidemics | 2 | 2024 | 516 | 0.240 |
Why?
|
Longevity | 2 | 2023 | 1083 | 0.240 |
Why?
|
Young Adult | 19 | 2024 | 59939 | 0.230 |
Why?
|
Diabetes Complications | 3 | 2021 | 1319 | 0.230 |
Why?
|
Developed Countries | 3 | 2023 | 453 | 0.220 |
Why?
|
Body Height | 2 | 2020 | 1562 | 0.210 |
Why?
|
Tuberculosis | 3 | 2024 | 2011 | 0.210 |
Why?
|
Metabolic Diseases | 2 | 2022 | 686 | 0.210 |
Why?
|
Aspirin | 2 | 2024 | 3134 | 0.200 |
Why?
|
HIV Integrase Inhibitors | 1 | 2024 | 165 | 0.190 |
Why?
|
Women | 2 | 2021 | 225 | 0.190 |
Why?
|
Alanine | 1 | 2024 | 613 | 0.190 |
Why?
|
Tobacco, Smokeless | 1 | 2022 | 132 | 0.190 |
Why?
|
Drug Substitution | 1 | 2024 | 292 | 0.180 |
Why?
|
Cohort Studies | 9 | 2024 | 41706 | 0.180 |
Why?
|
Leadership | 2 | 2021 | 1394 | 0.180 |
Why?
|
Zambia | 1 | 2022 | 273 | 0.180 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2024 | 3250 | 0.180 |
Why?
|
Anti-Obesity Agents | 1 | 2024 | 241 | 0.180 |
Why?
|
Housing | 2 | 2018 | 683 | 0.180 |
Why?
|
United States | 12 | 2023 | 72945 | 0.170 |
Why?
|
Latin America | 2 | 2022 | 416 | 0.170 |
Why?
|
Emigration and Immigration | 1 | 2022 | 405 | 0.160 |
Why?
|
Adolescent | 18 | 2024 | 88902 | 0.160 |
Why?
|
Program Evaluation | 2 | 2018 | 2504 | 0.160 |
Why?
|
Nicaragua | 1 | 2018 | 29 | 0.160 |
Why?
|
Economic Development | 1 | 2019 | 72 | 0.160 |
Why?
|
Secondary Prevention | 2 | 2023 | 1469 | 0.150 |
Why?
|
Life Expectancy | 2 | 2023 | 1248 | 0.150 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2023 | 3446 | 0.150 |
Why?
|
Hypotension, Orthostatic | 1 | 2021 | 258 | 0.150 |
Why?
|
Population Density | 1 | 2018 | 193 | 0.150 |
Why?
|
Burkina Faso | 3 | 2024 | 88 | 0.150 |
Why?
|
Health Expenditures | 1 | 2010 | 2389 | 0.140 |
Why?
|
Malnutrition | 1 | 2024 | 629 | 0.140 |
Why?
|
Cytomegalovirus Infections | 1 | 2024 | 838 | 0.140 |
Why?
|
Case Management | 1 | 2019 | 276 | 0.140 |
Why?
|
Population Surveillance | 2 | 2018 | 2594 | 0.140 |
Why?
|
Social Class | 3 | 2022 | 2007 | 0.140 |
Why?
|
Depression | 3 | 2024 | 8225 | 0.140 |
Why?
|
Posture | 1 | 2021 | 955 | 0.140 |
Why?
|
Los Angeles | 1 | 2017 | 244 | 0.130 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2018 | 426 | 0.130 |
Why?
|
Interviews as Topic | 4 | 2019 | 2741 | 0.130 |
Why?
|
Sexual Partners | 1 | 2021 | 804 | 0.130 |
Why?
|
Endemic Diseases | 1 | 2016 | 190 | 0.130 |
Why?
|
Cultural Diversity | 1 | 2019 | 370 | 0.120 |
Why?
|
Texas | 1 | 2016 | 410 | 0.120 |
Why?
|
Glomerular Filtration Rate | 1 | 2024 | 2232 | 0.120 |
Why?
|
Florida | 1 | 2016 | 417 | 0.120 |
Why?
|
Risk-Taking | 1 | 2021 | 1022 | 0.120 |
Why?
|
Cognition | 2 | 2024 | 7057 | 0.120 |
Why?
|
Fitness Centers | 1 | 2014 | 13 | 0.120 |
Why?
|
Prospective Studies | 4 | 2024 | 54872 | 0.120 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2022 | 1374 | 0.120 |
Why?
|
Government Programs | 1 | 2017 | 278 | 0.120 |
Why?
|
Overweight | 2 | 2023 | 2447 | 0.120 |
Why?
|
Health Policy | 2 | 2017 | 2697 | 0.120 |
Why?
|
Referral and Consultation | 3 | 2021 | 3618 | 0.120 |
Why?
|
Aging | 4 | 2021 | 8728 | 0.110 |
Why?
|
Systems Analysis | 1 | 2015 | 168 | 0.110 |
Why?
|
Health Care Costs | 2 | 2018 | 3240 | 0.110 |
Why?
|
New York | 1 | 2016 | 879 | 0.110 |
Why?
|
Focus Groups | 1 | 2020 | 1459 | 0.110 |
Why?
|
Growth Disorders | 1 | 2019 | 634 | 0.110 |
Why?
|
Fruit | 1 | 2019 | 1166 | 0.110 |
Why?
|
Health | 1 | 2017 | 396 | 0.110 |
Why?
|
Vegetables | 1 | 2019 | 1199 | 0.110 |
Why?
|
Epidemiologic Research Design | 1 | 2017 | 368 | 0.110 |
Why?
|
China | 3 | 2024 | 2386 | 0.110 |
Why?
|
Schools, Medical | 1 | 2020 | 882 | 0.110 |
Why?
|
Disease Vectors | 1 | 2013 | 61 | 0.100 |
Why?
|
Chronic Disease | 2 | 2020 | 9358 | 0.100 |
Why?
|
Indonesia | 2 | 2024 | 131 | 0.100 |
Why?
|
California | 1 | 2016 | 1435 | 0.100 |
Why?
|
Echocardiography, Stress | 1 | 2013 | 137 | 0.100 |
Why?
|
HIV Antibodies | 1 | 2019 | 1337 | 0.100 |
Why?
|
Pyrethrins | 1 | 2012 | 47 | 0.100 |
Why?
|
Logistic Models | 2 | 2020 | 13276 | 0.100 |
Why?
|
Cholesterol | 1 | 2021 | 2904 | 0.100 |
Why?
|
Weight Loss | 1 | 2023 | 2712 | 0.100 |
Why?
|
Parasitic Diseases | 1 | 2012 | 76 | 0.100 |
Why?
|
Guatemala | 1 | 2012 | 161 | 0.090 |
Why?
|
Diet | 2 | 2020 | 8088 | 0.090 |
Why?
|
Alcohol Drinking | 2 | 2022 | 4045 | 0.090 |
Why?
|
Continuity of Patient Care | 1 | 2018 | 1077 | 0.090 |
Why?
|
Sex Characteristics | 2 | 2020 | 2645 | 0.090 |
Why?
|
Sexual Behavior | 1 | 2021 | 2193 | 0.090 |
Why?
|
Hyperglycemia | 1 | 2019 | 1389 | 0.090 |
Why?
|
Incidence | 5 | 2024 | 21527 | 0.090 |
Why?
|
Urban Health | 1 | 2013 | 532 | 0.090 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 550 | 0.080 |
Why?
|
Aged, 80 and over | 8 | 2024 | 59548 | 0.080 |
Why?
|
Decision Support Techniques | 2 | 2011 | 2007 | 0.080 |
Why?
|
Fasting | 3 | 2021 | 1609 | 0.080 |
Why?
|
Glucose | 1 | 2021 | 4340 | 0.080 |
Why?
|
Decision Support Systems, Clinical | 1 | 2018 | 1178 | 0.080 |
Why?
|
Respiration, Artificial | 1 | 2020 | 2727 | 0.080 |
Why?
|
HIV Seronegativity | 2 | 2020 | 209 | 0.080 |
Why?
|
Quality Assurance, Health Care | 1 | 2019 | 2171 | 0.080 |
Why?
|
Pregnancy | 2 | 2023 | 30236 | 0.080 |
Why?
|
Sensitivity and Specificity | 3 | 2019 | 14653 | 0.080 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2020 | 2039 | 0.080 |
Why?
|
Research | 1 | 2017 | 1977 | 0.080 |
Why?
|
Odds Ratio | 1 | 2020 | 9661 | 0.070 |
Why?
|
Body Weights and Measures | 2 | 2019 | 208 | 0.070 |
Why?
|
Hospitals | 1 | 2021 | 3885 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10384 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3384 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2020 | 3235 | 0.060 |
Why?
|
Quality of Health Care | 1 | 2020 | 4306 | 0.060 |
Why?
|
Environmental Monitoring | 1 | 2012 | 1467 | 0.060 |
Why?
|
Models, Theoretical | 2 | 2021 | 3563 | 0.060 |
Why?
|
Pulmonary Embolism | 1 | 2018 | 2596 | 0.060 |
Why?
|
Insurance, Health | 1 | 2017 | 2520 | 0.060 |
Why?
|
Severity of Illness Index | 3 | 2019 | 15912 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2022 | 5753 | 0.060 |
Why?
|
International Cooperation | 1 | 2010 | 1434 | 0.060 |
Why?
|
Chile | 1 | 2024 | 258 | 0.050 |
Why?
|
Quality of Life | 3 | 2021 | 13476 | 0.050 |
Why?
|
Exercise | 2 | 2023 | 5945 | 0.050 |
Why?
|
Age Distribution | 2 | 2019 | 2869 | 0.050 |
Why?
|
C-Reactive Protein | 2 | 2017 | 3853 | 0.050 |
Why?
|
Health Care Surveys | 2 | 2020 | 2425 | 0.050 |
Why?
|
Neglected Diseases | 1 | 2022 | 67 | 0.050 |
Why?
|
Coronary Artery Disease | 2 | 2013 | 6575 | 0.050 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2023 | 216 | 0.050 |
Why?
|
HIV-1 | 1 | 2019 | 6948 | 0.050 |
Why?
|
Age Factors | 4 | 2021 | 18397 | 0.050 |
Why?
|
Coronary Angiography | 1 | 2013 | 4525 | 0.050 |
Why?
|
Review Literature as Topic | 1 | 2023 | 297 | 0.050 |
Why?
|
Smoking | 3 | 2024 | 9077 | 0.040 |
Why?
|
Sex Ratio | 1 | 2021 | 107 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 3 | 2013 | 1740 | 0.040 |
Why?
|
Saint Vincent and the Grenadines | 1 | 2020 | 2 | 0.040 |
Why?
|
Guyana | 1 | 2020 | 17 | 0.040 |
Why?
|
Brazil | 1 | 2024 | 1250 | 0.040 |
Why?
|
Serologic Tests | 1 | 2022 | 382 | 0.040 |
Why?
|
Bhutan | 1 | 2020 | 61 | 0.040 |
Why?
|
Georgia | 1 | 2020 | 186 | 0.040 |
Why?
|
Electrocardiography | 1 | 2013 | 6408 | 0.040 |
Why?
|
Cytomegalovirus | 1 | 2024 | 754 | 0.040 |
Why?
|
Health Systems Plans | 1 | 2019 | 20 | 0.040 |
Why?
|
Regression Analysis | 2 | 2019 | 6329 | 0.040 |
Why?
|
Namibia | 1 | 2019 | 28 | 0.040 |
Why?
|
Antigens, CD19 | 1 | 2022 | 444 | 0.040 |
Why?
|
Clinical Competence | 1 | 2015 | 4858 | 0.040 |
Why?
|
Muscles | 1 | 2024 | 1576 | 0.040 |
Why?
|
Nepal | 1 | 2020 | 302 | 0.040 |
Why?
|
Frail Elderly | 1 | 2024 | 781 | 0.040 |
Why?
|
Disease Progression | 4 | 2024 | 13642 | 0.040 |
Why?
|
Prognosis | 3 | 2024 | 29959 | 0.040 |
Why?
|
Cell Count | 1 | 2022 | 1826 | 0.040 |
Why?
|
Comparative Effectiveness Research | 1 | 2023 | 713 | 0.040 |
Why?
|
Meta-Analysis as Topic | 1 | 2023 | 1365 | 0.040 |
Why?
|
Radiography, Thoracic | 1 | 2024 | 1320 | 0.040 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2024 | 836 | 0.040 |
Why?
|
Blood Chemical Analysis | 1 | 2019 | 434 | 0.040 |
Why?
|
Antifungal Agents | 1 | 2022 | 769 | 0.030 |
Why?
|
Markov Chains | 2 | 2013 | 974 | 0.030 |
Why?
|
Cardiovascular Agents | 1 | 2023 | 849 | 0.030 |
Why?
|
Kenya | 1 | 2020 | 757 | 0.030 |
Why?
|
World Health Organization | 1 | 2023 | 1327 | 0.030 |
Why?
|
Blood | 1 | 2019 | 598 | 0.030 |
Why?
|
Geography | 1 | 2018 | 651 | 0.030 |
Why?
|
Colombia | 1 | 2017 | 287 | 0.030 |
Why?
|
Research Personnel | 1 | 2021 | 589 | 0.030 |
Why?
|
Europe | 1 | 2022 | 3430 | 0.030 |
Why?
|
Waist-Hip Ratio | 1 | 2017 | 521 | 0.030 |
Why?
|
Heart Failure | 2 | 2011 | 11879 | 0.030 |
Why?
|
Risk Assessment | 3 | 2021 | 24299 | 0.030 |
Why?
|
HIV Seropositivity | 1 | 2020 | 962 | 0.030 |
Why?
|
Animals | 3 | 2018 | 168939 | 0.030 |
Why?
|
Editorial Policies | 1 | 2019 | 458 | 0.030 |
Why?
|
Specialization | 1 | 2019 | 779 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2021 | 1394 | 0.030 |
Why?
|
Cost-Benefit Analysis | 3 | 2013 | 5536 | 0.030 |
Why?
|
Sex Distribution | 1 | 2019 | 2274 | 0.030 |
Why?
|
Retrospective Studies | 4 | 2024 | 81657 | 0.030 |
Why?
|
Forecasting | 1 | 2022 | 2936 | 0.030 |
Why?
|
Gender Identity | 1 | 2019 | 767 | 0.030 |
Why?
|
Propensity Score | 1 | 2021 | 1972 | 0.030 |
Why?
|
Radiography | 1 | 2024 | 6968 | 0.030 |
Why?
|
Observer Variation | 1 | 2019 | 2614 | 0.030 |
Why?
|
Antibodies, Viral | 1 | 2024 | 3213 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2022 | 1503 | 0.020 |
Why?
|
Medication Adherence | 1 | 2024 | 2190 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2018 | 1667 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2024 | 4559 | 0.020 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2024 | 2763 | 0.020 |
Why?
|
Drug Costs | 1 | 2020 | 1194 | 0.020 |
Why?
|
Minority Groups | 1 | 2019 | 1208 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 1673 | 0.020 |
Why?
|
Mothers | 1 | 2022 | 2208 | 0.020 |
Why?
|
Disclosure | 1 | 2017 | 755 | 0.020 |
Why?
|
Mortality | 1 | 2022 | 2908 | 0.020 |
Why?
|
Child | 3 | 2024 | 80670 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15425 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2021 | 2779 | 0.020 |
Why?
|
Peru | 1 | 2013 | 888 | 0.020 |
Why?
|
Thailand | 1 | 2010 | 288 | 0.020 |
Why?
|
Community Health Services | 1 | 2014 | 659 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2013 | 20710 | 0.020 |
Why?
|
Computer Simulation | 1 | 2022 | 6258 | 0.020 |
Why?
|
Risk | 1 | 2021 | 9602 | 0.020 |
Why?
|
Condoms | 1 | 2010 | 336 | 0.020 |
Why?
|
Hospitalization | 1 | 2008 | 10816 | 0.020 |
Why?
|
Population Dynamics | 1 | 2010 | 314 | 0.020 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1217 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2018 | 5306 | 0.020 |
Why?
|
Registries | 1 | 2022 | 8352 | 0.020 |
Why?
|
Lipids | 1 | 2017 | 3322 | 0.020 |
Why?
|
Substance Abuse, Intravenous | 1 | 2010 | 530 | 0.020 |
Why?
|
Lung | 1 | 2024 | 10068 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 8045 | 0.010 |
Why?
|
Patient Compliance | 1 | 2014 | 2694 | 0.010 |
Why?
|
Health Status | 1 | 2017 | 4087 | 0.010 |
Why?
|
Primary Health Care | 1 | 2020 | 4735 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3411 | 0.010 |
Why?
|
Health Behavior | 1 | 2014 | 2649 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8734 | 0.010 |
Why?
|
Homosexuality, Male | 1 | 2010 | 1342 | 0.010 |
Why?
|
Cholesterol, LDL | 1 | 2010 | 2392 | 0.010 |
Why?
|
Infant | 1 | 2022 | 36459 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7870 | 0.010 |
Why?
|
Algorithms | 1 | 2018 | 14073 | 0.010 |
Why?
|
Models, Statistical | 1 | 2011 | 5092 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2021 | 21162 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2019 | 65286 | 0.010 |
Why?
|